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The Fig. 1 ), a novel, non-sedative histamine Hl-receptor antagonist, is cur rently under development for the treatment of bronchial asthma by inhalation.
Recently, a new generation of orally administered histamine H1 receptor antagonists, such as terfena dine1-3n, astemizole4-6), ebastine7 , and loratadine8), has been developed and classified as non-sedative antihista mines. These compounds are different from classical an tihistamines that cause side effects on the central ner vous system and have atropine-like effects3).
Although KAA-276 is similar to astemizole in chemi cal structure, the administration route distinguishes KAA-276, given by inhalation, from astemizole and the other antihistamines, which are given by oral administra tion.
The compound selectively inhibits 3H-mepyramine binding to guinea pig cerebellum preparations and has a washout resistant property in guinea pig ileum in vitro. In vivo, this compound inhibits histamine or antigen-in duced bronchoconstriction in rats and guinea pigs when inhaled in a small amount, in which case there is no inhi bition of histamine-induced cutaneous reaction or other systemic pharmacological actions. This in vivo effect is produced promptly following inhalation and continues at least for several hours. No noteworthy toxic signs were observed in 2-week oral and inhalation toxicity tests in rats and beagles.
In the present study, the absorption, distribution, and excretion of KAA-276 were investigated in male rats af ter single intratracheal administration of the 3H-labeled compound to obtain data on its metabolic fate. Materials and Methods
Labeled Compound
The free form of 3H-KAA-276 ( Fig. 1 , Lot No. TP 366) was synthesized at Daiichi Pure Chemicals Co., Ltd. The specific activity of 3H-KAA-276 was 4.72 GBq/mg; and the radiochemical purity, determined by high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC), was more than 97 °/ .
Animals
Male Wistar rats (SPF, Charles River Japan), 7-8 weeks old and weighing 204-271 g, were used. The rats, housed at a temperature of 23±2°C and a humidity of 55±15%, were given a standard diet NF; Oriental Yeast Co. Ltd.) and water. The animals were fasted overnight before and for 4 hr after dosing, but were given water ad libitum.
Drug Administration
3H-KAA-276 prepared by the addition of H 2SO4 to the free form was diluted with non-labeled KAA-276, and was administered to rats as an isotonic saline solu tion. The pH of the drug solution was about 6. For the intratracheal study, the rats were anesthe tized lightly with sodium pentobarbital, and a hole was made with a needle in a site just superior to the bifurca tion of the trachea. A polyethylene cannula (SP-10; Nat sume Seisakusho Co., Ltd.) was then introduced through this hole, and the drug was injected into the trachea via the cannula. The doses of administered drug were 10, 30, and 100 ug/kg; and the volume was 0.4 ml/ kg.
In oral and intravenous studies, the dose of administra tion was 30 ug/kg; and the volume was 2 ml/kg .
Measurement of Radioactivity
Radioactivity in each sample was counted with a liq uid scintillation counter (LSC-903; Aloka). The count ing efficiency was corrected by the channel ratio method using an external standard source.
Plasma Concentration
After intratracheal, oral, or intravenous administra tion of 3H-KAA 276, blood samples were collected at various intervals from a tail vein into heparinized tubes. The plasma (50 ul) obtained by centrifugation was dried at 40°C for more than 24 hr (the dry method), af ter which it was combusted in a sample oxidizer (Tri Carb 306; Packard). The radioactivity in each sample was counted after addition of 14 ml of Monophase-S (Packard).
Distribution Experiment
After intratracheal administration of 3H-KAA-276 (30 ug/kg) , each rat was anesthetized with ether; and a blood sample from the abdominal aorta was taken into a heparinized tube. After the animal had been killed by ex sanguination, the tissues or organs were isolated immedi ately. The samples were then weighed, and the radioac tivity was determined by the same procedure employed for the plasma samples (the dry method).
Excretion in Urine and Feces
After intratracheal administration of 3H-KAA-276 (30 ug/kg) , each rat was kept separately in a glass metabolism cage. Urine and feces were collected separately at various intervals for up to 168 hr. All air ex iting from the chambers was passed through a trap filled with distilled water. The rats were killed by ether treat ment at 168 hr after dosing. The urine sample was dilut ed with water to 100 ml, and the fecal sample was homogenized in 300 ml of water. The carcass was solubi lized by heating under reflux for 96 hr in 500 ml of 0.5 M sodium hydroxide and 20 ml of toluene. The carcass so lution was diluted with water to 1000 ml. Radioactivity in an aliquot of each sample solution was counted di rectly after addition of 10 ml of Atomlight (Du Pont NEN Research Products) for evaluation of total radioac tivity excreted (the wet method). Radioactivity in an ali quot of the trapped water from expired air was counted directly after addition of 10 ml of Hionic-fluor (Packa rd). In addition, the radioactivity in an aliquot of urine and feces samples was determined by the same proce dure as used for plasma and tissues samples (the dry method).
Excretion in Bile
The bile duct and trachea were canulated with poly ethylene cannula under ether and sodium pentobarbital anesthesia, and 3H-KAA-276 (30,ug/kg) was then in jected into the trachea. Thereafter the animals were placed in Bollman cages. Bile, urine, and feces were col lected at various intervals up to 48 hr after administra tion. The biliary sample was diluted with water to 50 ml. Radioactivity in an aliquot of solution was counted after addition of 10 ml of Hionic-fluor (Packard). Radioactivi ty in urine and feces was determined as described above (the wet method). The rats were killed by ether treat ment at 168 hr after administration, and the gastrointes tinal contents were removed. The radioactivity of the gastrointestinal contents was counted by the wet method. The radioactivity of the carcass was deter mined as described above. In addition, the radioactivity in an aliquot of bile sample was determined similarly as for the plasma and tissues samples (the dry method).
9. Entero-hepatic Circulation 3H-KAA-276 (30 ug/kg) was injected into the trachea of bile duct-cannulated rats, and the bile was col lected into an ice-cold container up to 6 hr. The bile (0.821 MBq/8 ml/kg) was then injected into the duode num of other bile duct-cannulated rats. The rats were placed in Bollman cages; and the bile, urine, and feces were collected at various intervals up to 48 hr after ad ministration. The rats were killed by ether treatment at 48 hr, and the gastrointestinal contents were removed. The radioactivity in the urine, feces, gastrointestinal con tents, and carcass was counted as described above (the wet method). In addition, the radioactivity in an aliquot of bile samples was determined by the dry method. Fig. 2 and Table I show the radioactivity concentra tions (as equivalents of free form KAA-276, the same below) in plasma and pharmacokinetic parameters after intratracheal, intravenous, and oral administration of 3H-KAA-276 (30 pg/kg) to male rats . The radioactivi ty concentration in the plasma after intratracheal ad ministration of 3H-KAA-276 reached a maximum con centration (Ca ., 11.61 ng eq. of KAA-276/ml) at 5 min after dosing. Then it declined with a half-life of 1.64 hr (2-8 hr).
Results

Comparison of the Drug Absorption by Different Dosage Routes
After intravenous administration, the maximum radioactivity concentration was observed to be 16.13 ng eq. of KAA-276/ml at 2 min and declined with a half-life of 2.13 hr. The AUC(o_24hr) after intratracheal or in travenous administration was 17.8 or 18 .0 ng eq. of KAA 276-hr/ml, respectively, i.e., nearly the same . On the other hand, by oral administration the concentration of 3H-KAA-276 reached Cm. (2.75 ng eq. of KAA 276/ml) at 30 min after dosing and declined with a half life of 4.10 hr. The AUC(o_8 hr) was 4.6 ng eq. of KAA 276 • hr/ml, equivalent to about 30% of the AUC (0_8 hr) af ter intravenous administration. Fig. 3 and Table I show the radioactivity concentra tions in the plasma and pharmacokinetic parameters af ter a single intratracheal administration at doses of 10, 30, and 100,ug/kg. AUCo_24 hr and Cma,, were increased dose dependently. The AUC (0-24 hr) after dosing with 10 pg/kg was 29% of that after dosing with 30µg/kg; and the AUC(o-24 hr) after the administration of 100 µg/kg was 3.2 times larger than that after administration of 30 pg/kg. The relationship between dose and AUC(o-24hr) was linear in a range of 10 to 100 pg/kg. Table II shows the radioactivity concentration in tis sues after intratracheal administration of 3H-KAA-276 (30,ug/kg) to male rats. Concentrations of radioactivity peaked at 15 min in all tissues except for testes, intesti nal tract, and urinary bladder. At 15 min after dosing, the radioactivity concentrations in the lungs, trachea, and liver were highest and 15 to 37 times higher than their plasma concentration (10.087 ng eq. of KAA-276/ ml). The radioactivity concentrations in the thyroid, pituitary, kidneys, esophagus, stomach, and pancreas were 4.6 8.5 times higher than the plasma concentra tion. Radioactivity equal to the plasma level was detect ed in the urinary bladder, skeletal muscle, thymus, large intestine, caecum, skin, and blood. In the epididymis, fat, eyeball, testes, cerebellum, spinal cord, and cerebrum, the radioactivity concentration was lower than the plasma one (4-44%). At 4 hr after administration, the radioactivity concen trations in the lungs, ileum, jejunum, liver, mandibular gland, urinary bladder and trachea were more than 10 times higher than the plasma concentration, and those in the harderian gland, kidneys, esophagus, caecum, and sublingual gland were 5 times higher. Then the radioac tivity gradually decreased in most of the tissues. At 24 hr after administration, the radioactivity in the mandibular gland was 10% of the maximum level. The concentration in other tissues, except the intestinal tis sues, was less than 5% of the maximum or below the de tection limit.
Relationship Between Dose and Absorption
Tissue Distribution of 3H-KAA-276
At 168 hr after administration, the radioactivity con centrations in trachea, liver, and kidneys were less than 1% of their maximum. In the other tissues, the radioac tivity concentrations were below the detection limit. Table III shows the cumulative excretion of radioac tivity in the urine, feces, and expired air after in tratracheal administration of 3H-KAA-276 (30 Mg/kg) to male rats. The excretion of radioactivity in the urine was 16.9% of the dose within 24 hr, 17.4% within 48 hr, and 17.8% within 168 hr. The excretion of radioactivity in the feces was 51.6% within 24 hr, 80.0 °% within 48 hr, and 82.1 °% within 168 hr. The cumulative radioactivi ty from expired air trapped in water was 0.2% of the dose within 168 hr. The residual radioactivity in the car cass at 168 hr after dosing was 0.4% of the dose.
Excretion in Urine and Feces
The percentage of tritiated water was 5.1% of the radioactivity in urine within 168 hr of dosing; however, no tritiated water was detected in feces within this time period.
Excretion in Bile
The cumulative excretion of radioactivity in bile, urine, and feces after intratracheal administration of 3H KAA-276 to bile duct-cannulated male rats is shown in Table IV . The excretion of radioactivity in the bile was 51.7% of the dose within 2 hr, 63.4% within 4 hr, and 75.3% within 48 hr after dosing. The excretion of radioactivity in urine and feces, determined simultane ously, was 18.1% and 3.8% of the dose within 48 hr af ter dosing, respectively. The residual radioactivity in the gastrointestinal contents and the carcass at 48 hr af ter dosing was 3.2% and 1.1 °/ of the dose, respectively.
The percentage of tritiated water was 5.8% of the radioactivity in the bile within 48 hr of dosing. 6. Entero-hepatic Circulation Bile was collected 0-6 hr after intratracheal adminis tration of 3H-KAA-276 to bile duct-cannulated male rats at a dose of 30,ug/kg. The bile was then injected into duodenum of other bile duct-cannulated rats.
Radioactivity was excreted in the bile in an amount equal to 14.4% of the dose within 4 hr, 32.5% within 24 hr, and 33A YO within 48 hr. The excretion of radioactivi ty in urine and feces, determined simultaneously, was 3.0% and 57.2% of the injection within 48 hr, respec tively (Table V) . The residual radioactivity in the gas trointestinal contents and the carcass at 48 hr was 4.10/ and 1.0% of the injection, respectively.
The percentage of tritiated water was 2.4% of the radioactivity in bile within 48 hr of dosing. 
Discussion
The radioactivity concentration in the plasma reached its maximum with in a few minutes after the in tratracheal administration of 3H-KAA-276 to male rats. The AUC after intratracheal administration was the same as that after intravenous administration (Table I) . Moreover, the absorption rate from the trachea was ex tremely fast, because almost the entire amount of radioactivity was excreted into the bile within 4 hr after dosing (Table IV) . To investigate the dose dependency in the drug absorption, we used the dose range of 10 to 100,ug/kg, which is the pharmacologically effective dose range. The Cmax and the AUC increased dose-de pendently, and a good correlation (rz=0.9994) was ob served between the dose and the AUC.
In the distribution study, the highest concentration was observed in the administration sites, the trachea and the lungs, at the first sampling point after the ad ministration (15 min, Table II ). Although most of tis sues showed many times higher concentration than the plasma level, the radioactivity was distributed poorly in the brain, eye balls, and testes. The data suggested that KAA-276 penetrated poorly through the blood-brain bar rier. Although the radioactivity was observed in the cae cum and large intestine, the concentration was almost equal to the plasma level, and also the muscle level. This may be due only to the systemic circulation. The elimina tion in most tissues was rapid, whereas higher concentra tions remained in the target tissues, the trachea and lung tissue, which included the bronchi, within 24 hr after the administration.
Some radioactivity was found in the esophagus and the stomach. As an explanation for this, a small amount of the drug injected into the trachea might have been transported towards the pharynx by the ciliary action in the respiratory tracts), and then passed into the gastroin testinal tract. The radioactivity level of the esophagus and the stomach, however, represented less than 5% of the total radioactivity. These results show that most of the drug administered via the trachea passed into the bronchi and possibly into the alveolar sacs, where it was absorbed well and rapidly. The excretion of radioactivity in urine and feces was almost completed within 48 hr after intratracheal ad ministration, and the ratio of radioactivity in the feces at that time was more than 80% of the dose (Table III) . In bile duct-cannulated rats at 48 hr after intratracheal administration, the radioactivity was recovered mainly in the bile (75.3 °%, Table IV ). In investigating the en terohepatic circulation, we found that at least 36% of the biliary excreta was re-absorbed, of which about 90% was re-excreted in the bile (Table V) . The ratio of radioactivity in the enterohepatic circulation was esti mated to be about 30% of the dose. These results show that KAA-276 was excreted mainly in bile, passed through the enterohepatic circulation, and consequently was excreted in the feces.
A large portion of the drug in the systemic circulation was extensively converted to metabolites oxidized on the carboxyethyl moiety and to conjugates. These rela tively inactive metabolites were identified in rat bile (da ta not shown). When the drug was administered orally, the bioavailability would be low due to the first-pass metabolism by the liver. For this reason, we assume that the unchanged KAA-276 (active form) concentration in the target tissues, the trachea and the bronchus, would not reach its effective level after oral administration without side effects. Therefore, local administration, such as intratracheal and nasal administration, will be ad vantageous over oral administration.
This study shows that intratracheal administration is able to deliver KAA-276 efficiently to the target tissues, the trachea and the bronchus. Thus, intratracheal ad ministration, including inhalation, is a particularly use ful administration route for KAA-276 in the treatment of bronchial asthma.
